相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review
Akisha Glasgow et al.
BREAST CANCER (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kevin Kalinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Martine Piccart et al.
LANCET ONCOLOGY (2021)
Clinical utility of genomic signatures in young breast cancer patients: a systematic review
Cynthia Villarreal-Garza et al.
NPJ BREAST CANCER (2020)
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Abiola F. Ibraheem et al.
CANCER (2019)
Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial
Hong-Yu Xiang et al.
CHINESE MEDICAL JOURNAL (2019)
Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer
Vahit Ozmen et al.
EUROPEAN JOURNAL OF BREAST HEALTH (2019)
Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study
Vahit Ozmen et al.
EUROPEAN JOURNAL OF BREAST HEALTH (2019)
Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30
Seho Park et al.
BREAST CANCER RESEARCH (2019)
Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time
Austin D. Williams et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers
Andre Filipe Vieira et al.
FRONTIERS IN MEDICINE (2018)
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14
Norman Wolmark et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations
N. Lynn Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey
Vahit Ozmen et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2016)
Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey
Vahit Ozmen et al.
JOURNAL OF BREAST HEALTH (2016)
Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age
Sandra M. Swain et al.
ADVANCES IN THERAPY (2015)
Breast Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients)
Vahit Ozmen
JOURNAL OF BREAST HEALTH (2014)
Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis
Helen Ingoldsby et al.
BREAST (2013)
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study
Lawrence J. Solin et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Impact of Progesterone Receptor Semiquantitative Immunohistochemical Result on Oncotype DX Recurrence Score
Beth Z. Clark et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor-Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer
James J. Dignam et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effects of young age at presentation on survival in breast cancer
Nagi S. El Saghir et al.
BMC CANCER (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Comparison of Fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial
A Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Do young breast cancer patients have worse outcomes?
MA Maggard et al.
JOURNAL OF SURGICAL RESEARCH (2003)
分享论文
